However, it is worth mentioning that CSPG4 is not generally expressed by ovarian cancer cells; therefore, it cannot be considered a target antigen for CAR-T therapy of ovarian cancer, but the results of this study can highlight the potential of this cell surface antigen as a secondary inducible target antigen for CAR-T therapy of various types of solid tumors including ovarian cancer. Here, CD53 is linked to ovarian cancer.